Executive moves: April

April was a busy month for healthcare executives with new CEOs, CMOs and COOs coming up for spring. See our list of top executive moves below:

  1. Andrew Bindman, MD, has been named director of the U.S. Agency for Healthcare Research and Quality (AHRQ), replacing Sharon B. Arnold, PhD, who has served as AHRQ’s Acting Director since the departure of Richard Kronick, PhD.
  1. Brigham and Women's Healthcare in Boston has named Adam Landman, MD, as its new chief information officer.
  1. Technology expert Jennifer “Jenna” Geiger has been hired as Alignment Healthcare’s first COO.
  1. The chief executive of Valeant Pharmaceuticals, J. Michael Pearson, has agreed to be deposed by a Senate committee investigating the causes of soaring prescription medicine prices.
  1. Canada-based Valeant Pharmaceuticals has named Joseph Papa CEO after he resigned from Allegan, Mich.-based Perrigo, according to Reuters.
  1. Los Angeles-based St. Vincent Medical Center has hired Frank Cracolici, RN, as CEO.
  1. Stanford Health Care names David Entwistle president and CEO.
  1. Mercy Health in Cincinnati has appointed Randall Curnow, MD, CMO of Mercy Health and president of Mercy Health Select, the system's accountable care organization.
  1. The American Hospital Association has named Maureen Swick, PhD, RN, the CEO of the American Organization of Nurse Executives and AHA senior vice president, nursing.
  1. Mercy Health - Cincinnati names Michael Garfield COO.
  1. Chicago-based Presence Health has appointed Jim Kelly as system CFO.
  1. Brent E. Christopher has been named president of Children's Medical Center Foundation, the fundraising arm of Dallas-based Children's Health.

 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.